Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival

British Journal of Haematology

Volumn 118, Issue 4, 2002, Pages 1034-1040

  Mateos, Maria V ^a   García Sanz, Ramón ^a,b,c   López Pérez, Ricardo ^a,b   Moro, Maria J ^c   Ocio, Enrique ^b   Hernández, Jose ^c   Megido, Marta ^c   Caballero, Maria D ^a   Fernández Calvo, Javier ^c   Bárez, Abelardo ^c   Almeida, Julia ^b,d   Orfão, Alberto ^b,d   González, Marcos ^a,b,c   San Miguel, Jesús F ^a,b,c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c Grupo Castellano Leonés para el Estudio de las Gammapatías Monoclonales   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Multiple myeloma; P16 methylation

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; PROTEIN P16; RESTRICTION ENDONUCLEASE;

ADULT; AGED; ARTICLE; CELL ASSAY; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; GENE INACTIVATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METHYLATION; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PLASMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; SURVIVAL; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CELL DIVISION; DNA METHYLATION; FEMALE; FLOW CYTOMETRY; GENES, P16; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PLASMA CELLS; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 18544379572     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03749.x     Document Type: Article

References (37)

1. High incidence of translocations t(11; 14) (q13;q32) and t(4; 14) (p16;q32) in patients with plasma cell malignancies
2. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: A randomized multicentric study of 487 patients
3. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines
4. Proposed guideline for protocol studies. II. Plasma cell myeloma
5. Abnormal cell cycle regulation in malignancy
6. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cell
7. Pretreatment tumor mass, cell kinetics and prognostic in multiple myeloma
8. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features
9. Multiple myeloma and the translocation t (11; 14) (q13;q32): A report on 13 cases
10. Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas
11. De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis
12. Intensive treatment of multiple myeloma and criteria for complete remission
13. Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
14. Multiple myeloma: Increasing evidence for a multistep transformation process
15. The hallmarks of cancer
16. Prognostic importance of p15 and p16 gene inactivation in childhood acute lymphocytic leukemia
17. Role of the cyclin dependent kinase inhibitors in the development of cancer
18. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
19. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome
20. Role of the p16 tumor suppressor gene in cancer
21. Retinoblastoma protein dependent cell cycle inhibition by the tumour suppressor p16
22. p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies
23. Frequent hypermethylation of p16 and p15 genes in multiple myeloma
24. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma
25. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique
26. Prognostic value of numerical chromosome aberrations in multiple myeloma: A fish analysis of 15 different chromosomes
27. INK4a gene inactivation by deletion, mutations and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas
28. A new staging system for multiple myeloma based on the number of S-phase plasma cells
29. Treatment of multiple myeloma
30. Prognostic value of cytogenetics in multiple myeloma
31. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
32. Complex structure and regulation of the p16 (MTS1) locus
33. Analysis of the p16INK4a, 15INK4b and p18INK4c genes in multiple myeloma
34. Methylation of the p16INK4a gene in multiple myeloma
35. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
36. The retinoblastoma protein and cell cycle control
37. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization